hCRF
Phase 3Small molecule
hCRF is one of 8 small molecule programs targeting Brain Edema. It is currently in Phase 3.
1
Indications
3
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Brain Edema
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Alka-Seltzer
AAbbott
Approved
Glibenclamide
Novo NordiskPhase 2
hCRF
CCeltic Pharma Development Services
Phase 3
Plasmalyte
SSeoul National University Hospital
Phase 1
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Xerecept
CCeltic Pharma Development Services
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dexamethasone1 trial
TED1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hCRF. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details